Rally Researchers

One Mission, 51 Childhood Cancer Researchers, $3.4 Million in Grants

One Mission, 51 Childhood Cancer Researchers, $3.4 Million in Grants

bCSRally Foundation for Childhood Cancer Research Awards $3.4 Million in Grants This year, 51 researchers from 31 institutions across the country and worldwide will receive a total of $3.4 million in grants from Rally Foundation for Childhood Cancer Research. “Rally Foundation has now awarded $25.4 million in grants for childhood cancer research since we started in 2005,” says Dean Crowe, Founder and CEO. “From the beginning, our mission has been to fund the best research wherever it may be to help find better childhood cancer treatments with fewer long-term side effects and, ultimately, cures.” Rally grants are awarded based on a competitive dual peer-review process conducted by Rally’s Medical Advisory Board, which is made up of 60 leading childhood cancer experts. These grants fund all levels of research, from science at the bench to translational, and they include second- and...

read more
Pediatric Cancer Dad Discovers a Promising Novel Approach to Wilms’ Tumors

Pediatric Cancer Dad Discovers a Promising Novel Approach to Wilms’ Tumors

Rally Foundation for Childhood Cancer Research (Rally) likes funding outside-the-box ideas and, at times, funding outside-of-the-box researchers: those who we normally not consider as a scientific researcher. Rally is thrilled to share recent developments from an outside-the-box researcher and his study of Wilms’ Tumor. The study emerges from the Children’s Cancer Therapy Development Institute (cc-TDI) in Beaverton, Oregon, in collaboration with Memorial Sloan Kettering Cancer Center. Rally-funded researcher Andy Woods leads the study published in Pediatric Blood & Cancer (link Pediatric Blood & Cancer). But first, who is this outside-of-the-box researcher Andy Woods? Andy Woods is a college-educated stone and tile mason from Montana. He is also a Dad. A dad who heard the devasting words, “Your child has cancer.” When his daughter, Stellablue, was four years old, she was...

read more
What are Oncolytic Viruses?

What are Oncolytic Viruses?

A key part of Rally’s mission is to find better treatments with fewer long-term side effects, and for almost a decade. Rally has invested for almost a decade in oncolytic virus treatments. A promising, cutting-edge, targeted immunotherapy. Oncolytic viruses are genetically modified viruses or naturally occurring viruses that are reprogrammed to selectively replicate in cancer cells killing the cancer without damaging normal cells. Pretty cool. Josh Bernstock, M.D., Ph.D., shares, “Oncolytic virotherapy is a rapidly progressing field in oncology that uses oncolytic viruses to selectively infect cancer cells and cause an antitumor response through direct destruction of the tumor and stimulation of the immune system.” “This direct targeting of tumor cells is efficacious and non-toxic. In the article below we highlight critical components of the immune microenvironment of brain tumors. In...

read more
New and Innovative Study Technique for Osteosarcoma Metastasis

New and Innovative Study Technique for Osteosarcoma Metastasis

Osteosarcoma (OS) is a type of cancer that begins in the cells that form bones, and mainly affects teenagers and young adults. In metastatic osteosarcoma, the cancer spreads from the primary bone site to another location, most often the lungs. It can also spread to other bones, the brain or other organs. Currently there are no curative treatments for metastatic osteosarcoma. We urgently need to develop new therapies. To better understand a disease, it is common for tumor research studies to use orthotopic implantation. This method grafts tumor tissue where the disease begins in a mouse model. For osteosarcoma studies that would be in a bone allowing researchers to examine cancer progression more accurately and identify potential drug combinations more reliably. Rally-funded researcher Lindsay Jones Talbot, MD, is a pediatric surgeon, researcher, and instructor at St. Jude Children’s...

read more
INSTRuCT Database for Rhabdomyosarcoma Impact

INSTRuCT Database for Rhabdomyosarcoma Impact

Rally is proud to be the initial funder for the creation of the INSTRuCT Database with a Consortium Grant to Dr. Sam Volchenboum of the Pediatric Cancer Data Commons (PCDC) at the University of Chicago. Recent advances in genomic medicine look promising in the study of rhabdomyosarcoma (RMS). RMS is a rare soft tissue malignancy primarily diagnosed before adolescence.   RMS studies are historically challenged, given that only approximately 350 patients are diagnosed with RMS each year in the United States and around 700 patients a year in Western Europe. It is challenging to conduct clinical trials of anticancer drugs for the treatment of RMS due to the rarity, its various subtypes and differences in gene mutations. As a solution, the International Soft-Tissue Sarcoma Database Consortium (INSTRuCT) was created through collaboration with the Children’s Oncology Group (COG) Soft-Tissue...

read more
New RNA Therapies for Glioblastoma from Small Phase 1 Study

New RNA Therapies for Glioblastoma from Small Phase 1 Study

Glioblastoma (GBM) in children and adults is a deadly brain tumor with a poor prognosis. Current treatment includes surgery to remove as much of the tumor as possible, followed by radiation and chemotherapy. Unfortunately, most patients still experience tumor growth despite the treatment and have a median survival of less than two years.  Immunotherapy has shown success in the treatment of other types of tumors, but that success has been elusive with malignant brain tumors, such as GBM. However, new ribonucleic acid (RNA) based immunotherapy is showing promise in treatment for GBM. Rally-funded researcher Elias Sayour, MD, PhD, and his team at the University of Florida recently published exciting discoveries focusing on the utilization of RNA dendritic cell (DC) vaccines and RNA nanoparticle therapies in the treatment of GBM. RNA-based therapies offer clear advantages over other...

read more

$

Sign up for our emails!

Fill out my online form.

Recent Posts

Rally Researchers

One Mission, 51 Childhood Cancer Researchers, $3.4 Million in Grants

One Mission, 51 Childhood Cancer Researchers, $3.4 Million in Grants

bCSRally Foundation for Childhood Cancer Research Awards $3.4 Million in Grants This year, 51 researchers from 31 institutions across the country and worldwide will receive a total of $3.4 million in grants from Rally Foundation for Childhood Cancer Research. “Rally Foundation has now awarded $25.4 million in grants for childhood cancer research since we started in 2005,” says Dean Crowe, Founder and CEO. “From the beginning, our mission has been to fund the best research wherever it may be to...

read more
Pediatric Cancer Dad Discovers a Promising Novel Approach to Wilms’ Tumors

Pediatric Cancer Dad Discovers a Promising Novel Approach to Wilms’ Tumors

Rally Foundation for Childhood Cancer Research (Rally) likes funding outside-the-box ideas and, at times, funding outside-of-the-box researchers: those who we normally not consider as a scientific researcher. Rally is thrilled to share recent developments from an outside-the-box researcher and his study of Wilms’ Tumor. The study emerges from the Children’s Cancer Therapy Development Institute (cc-TDI) in Beaverton, Oregon, in collaboration with Memorial Sloan Kettering Cancer Center....

read more
What are Oncolytic Viruses?

What are Oncolytic Viruses?

A key part of Rally’s mission is to find better treatments with fewer long-term side effects, and for almost a decade. Rally has invested for almost a decade in oncolytic virus treatments. A promising, cutting-edge, targeted immunotherapy. Oncolytic viruses are genetically modified viruses or naturally occurring viruses that are reprogrammed to selectively replicate in cancer cells killing the cancer without damaging normal cells. Pretty cool. Josh Bernstock, M.D., Ph.D., shares, “Oncolytic...

read more
New and Innovative Study Technique for Osteosarcoma Metastasis

New and Innovative Study Technique for Osteosarcoma Metastasis

Osteosarcoma (OS) is a type of cancer that begins in the cells that form bones, and mainly affects teenagers and young adults. In metastatic osteosarcoma, the cancer spreads from the primary bone site to another location, most often the lungs. It can also spread to other bones, the brain or other organs. Currently there are no curative treatments for metastatic osteosarcoma. We urgently need to develop new therapies. To better understand a disease, it is common for tumor research studies to...

read more
INSTRuCT Database for Rhabdomyosarcoma Impact

INSTRuCT Database for Rhabdomyosarcoma Impact

Rally is proud to be the initial funder for the creation of the INSTRuCT Database with a Consortium Grant to Dr. Sam Volchenboum of the Pediatric Cancer Data Commons (PCDC) at the University of Chicago. Recent advances in genomic medicine look promising in the study of rhabdomyosarcoma (RMS). RMS is a rare soft tissue malignancy primarily diagnosed before adolescence.   RMS studies are historically challenged, given that only approximately 350 patients are diagnosed with RMS each year in the...

read more
New RNA Therapies for Glioblastoma from Small Phase 1 Study

New RNA Therapies for Glioblastoma from Small Phase 1 Study

Glioblastoma (GBM) in children and adults is a deadly brain tumor with a poor prognosis. Current treatment includes surgery to remove as much of the tumor as possible, followed by radiation and chemotherapy. Unfortunately, most patients still experience tumor growth despite the treatment and have a median survival of less than two years.  Immunotherapy has shown success in the treatment of other types of tumors, but that success has been elusive with malignant brain tumors, such as GBM....

read more

$

Sign up for our emails!

Fill out my online form.

Recent Posts

Volunteers are the heart of Rally's mission!

 

Enter your email below to receive details about our volunteer opportunities.

Thank you for your interest in volunteering with Rally! You should receive an email shortly with additional details.

X